IXEMPRA
Drug
R-PHARM US LLC
Total Payments
$327,207
Transactions
37
Doctors
19
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $141.28 | 3 | 3 |
| 2021 | $3,939 | 3 | 2 |
| 2020 | $323,091 | 28 | 11 |
| 2018 | $35.93 | 3 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $313,416 | 6 | 95.8% |
| Honoraria | $12,000 | 10 | 3.7% |
| Food and Beverage | $1,626 | 19 | 0.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $125.28 | 1 | 0.0% |
| Travel and Lodging | $39.49 | 1 | 0.0% |
Payments by Type
Research
$313,416
6 transactions
General
$13,791
31 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A randomized phase II evaluation of weekly ixabepilone with or without biweekly bevacizumab in recurrent or persistent platinum-resistant/refractory epithelial ovarian, fallopian tube, or primary peritoneal cancers | R-Pharm US LLC | $313,416 | 0 |
Top Doctors Receiving Payments for IXEMPRA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New Haven, CT | $313,416 | 6 |
| , MD | Internal Medicine | San Juan, PR | $1,502 | 3 |
| , MD | Hematology & Oncology | Bayamon, PR | $1,365 | 3 |
| , M.D | Oncology | Carolina, PR | $1,326 | 2 |
| , M.D | Specialist | Ponce, PR | $1,326 | 2 |
| , M.D | Hematology & Oncology | San Juan, PR | $1,326 | 2 |
| , MD | Internal Medicine | San Juan, PR | $1,326 | 2 |
| , MD | Hematology & Oncology | Humacao, PR | $1,326 | 2 |
| , M.D | Hematology & Oncology | Bayamon, PR | $1,326 | 2 |
| , MD | Hematology & Oncology | Carolina, PR | $1,326 | 2 |
| , MD | Hematology & Oncology | San Juan, PR | $1,326 | 2 |
| , M.D | Medical Oncology | Houston, TX | $125.28 | 1 |
| , MD | Medical Oncology | Houston, TX | $104.31 | 1 |
| , MD | Internal Medicine | San Jose, CA | $23.07 | 1 |
| , MD | Specialist | Pittsburgh, PA | $15.61 | 1 |
| , MD | Hematology & Oncology | Louisville, KY | $12.45 | 1 |
| , MD | Hematology & Oncology | Memphis, TN | $11.74 | 1 |
| , M.D | Hematology & Oncology | Memphis, TN | $11.74 | 1 |
| , M.D | Specialist | Zion, IL | $9.00 | 1 |
| , MD | Medical Oncology | Lebanon, NH | $7.00 | 1 |
Ad
Manufacturing Companies
- R-Pharm US LLC $313,573
- R-PHARM US LLC $13,575
- Kyowa Kirin, Inc. $35.93
- E.R. Squibb & Sons, L.L.C. $23.07
Product Information
- Type Drug
- Total Payments $327,207
- Total Doctors 19
- Transactions 37
About IXEMPRA
IXEMPRA is a drug associated with $327,207 in payments to 19 healthcare providers, recorded across 37 transactions in the CMS Open Payments database. The primary manufacturer is R-PHARM US LLC.
Payment data is available from 2018 to 2022. In 2022, $141.28 was paid across 3 transactions to 3 doctors.
The most common payment nature for IXEMPRA is "Unspecified" ($313,416, 95.8% of total).
IXEMPRA is associated with 1 research study, including "A randomized phase II evaluation of weekly ixabepilone with or without biweekly bevacizumab in recurrent or persistent platinum-resistant/refractory epithelial ovarian, fallopian tube, or primary peritoneal cancers" ($313,416).